Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib

Approximately 40% of chronic myeloid leukemia (CML) patients who discontinue imatinib (IM) therapy maintain undetectable minimal residual disease (UMRD) for more than one year (stopping IM (STOP-IM)). To determine a possible biomarker for STOP-IM CML, we examined plasma miRNA expression in CML patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohyashiki, Kazuma, Umezu, Tomohiro, Katagiri, Seiichiro, Kobayashi, Chiaki, Azuma, Kenko, Tauchi, Tetsuzo, Okabe, Seiichi, Fukuoka, Yutaka, Ohyashiki, Junko H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849026/
https://www.ncbi.nlm.nih.gov/pubmed/27092489
http://dx.doi.org/10.3390/ijms17040570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849026/
https://www.ncbi.nlm.nih.gov/pubmed/27092489
http://dx.doi.org/10.3390/ijms17040570

Ejemplares similares